Full Breakdown
Concerns Over Accuracy of Dexcom's G7 Continuous Glucose Monitor
12/10/2025, 12:41:10 AM
Overview of the G7 Continuous Glucose Monitor
In early 2023, Dan Heller began testing Dexcom’s latest continuous glucose monitor (CGM), the G7, alongside its predecessor, the G6. Dexcom, a San Diego-based healthcare company, marketed the G7 as the “most accurate sensor” for individuals with Type 1 diabetes. However, Heller's findings, shared in a September 2023 post, indicated that the G7's real-world performance did not meet expectations, leading him to predict an increase in adverse events associated with the device. Reports from numerous users have echoed Heller's concerns, particularly regarding erratic and inaccurate glucose readings, prompting the formation of a Facebook group for sharing negative experiences and several class action lawsuits against Dexcom for alleged false advertising.
Technical Background and Performance Metrics
Continuous glucose monitors, including the G7, consist of a filament inserted under the skin that generates electrical signals in response to glucose. These signals are processed to provide glucose readings every few minutes. The G7 introduced improvements over the G6, including a smaller design and an updated algorithm for enhanced accuracy. Despite these advancements, discrepancies between clinical trial results and user experiences have emerged. The U.S. Food and Drug Administration (FDA) issued a warning letter in March 2025 regarding a component change that negatively impacted some sensor batches, although this material has since been removed.
Accuracy Standards and User Experience
The accuracy of CGMs is often quantified using the mean absolute relative difference (MARD), with lower percentages indicating higher accuracy. While Dexcom advertises a MARD around 8 percent, independent studies have reported higher values, suggesting that the G7 may not perform as well in real-world conditions. Factors such as physiological differences among users and variations in glucose levels across blood compartments can contribute to these discrepancies. Critics argue that the design of clinical trials can influence reported accuracy, as they may not fully replicate the conditions users encounter.
Criticism and Calls for Standardization
Experts like Manuel Eichenlaub, a biomedical engineer at the Institute for Diabetes Technology Ulm, advocate for more rigorous and standardized testing protocols for CGMs. Eichenlaub and colleagues have proposed comprehensive guidelines to improve performance testing, emphasizing the need for consistency across manufacturers. Heller, representing the user perspective, stresses the importance of actionable data over mere accuracy metrics, urging engineers to prioritize patient needs in their designs.
Official Responses from Dexcom
Dexcom's senior vice president of innovation and sensor technology, Peter Simpson, maintains that the G7 is one of the most accurate glucose sensors available, acknowledging variability in individual sensor performance. He asserts that the company meets FDA expectations in its trial protocols and continues to work closely with the FDA to address any concerns. Despite the challenges, Simpson emphasizes that the accuracy of CGMs remains a critical focus for Dexcom.
Conclusion: The Broader Implications
The ongoing concerns surrounding the G7's accuracy reflect a broader issue within the CGM market, as evidenced by Abbott's recent recall of 3 million sensors due to inaccurate readings. As the demand for reliable diabetes management tools grows, the need for standardized testing and transparent communication about device performance becomes increasingly vital for both manufacturers and users.
